(page 1012) have found an association between t(11;18)(q21;q21) of gastric MALT lymphomas and CagA strains of H pylori. Furthermore, they show that t(11;18)(q21; q21)-positive MZLs of MALT in other sites do occur, however, in a nonrandom fashion (ie, 38% and 24% in the lung and stomach, respectively, versus 1% in the salivary gland). Ye et al's proposal that the missing link might be chromosomal damage caused by oxidative stress induced by coinfiltrating neutrophils is intriguing. All the more so since this hypothesis is supported by data from Rollinson and colleagues (page 1007). Fascinatingly, using a completely different line of argument, these authors arrive at the very same conclusion. They show that, in their series of gastric MZLs, the glutathione S-transferase GST T1 null genotype and the Interleukin-1 RN2/2 genotype, but not the GST M1 null genotype or Interleukin-1 RN1/1 genotype, are associated with gastric MZLs. Thus, interindividual variations in inflammatory responses and differences in antioxidative capacity may be the genetic background on which H pylori can eventually exert its oncogenic potential. At this stage, it is certainly very important to investigate whether this interindividual variation of inflammatory response might even lead to a specific genetically defined subset of MZLs.
-Thomas F. E. Barth and Peter Mö ller

University of Ulm, Germany
A profile of mycosis fungoides
Mycosis fungoides is the most common primary lymphoproliferative disorder of skin. The disease may be difficult to diagnose, particularly in the early patch and plaque stages, when it may resemble a chronic inflammatory dermatitis. The neoplastic cells of mycosis fungoides are CD3 ϩ T cells, which are usually CD4 ϩ T helper cells, and may or may not exhibit an aberrant immunophenotype, with loss of CD7 expression. A number of nonneoplastic conditions, including inflammatory dermatoses, may exhibit an identical immunophenotype, adding to the difficulty of early diagnosis. Often, the diagnosis becomes evident only after multiple biopsies, over a period of months to years. With disease progression, increasing epidermotropism and cytologic atypia are seen, allowing for more definitive diagnosis. With advanced-stage disease, skin tumors may form and neoplastic cells may spread to extracutaneous sites. The pathogenesis of mycosis fungoides is unknown.
In this issue, Tracey and colleagues (page 1042) apply gene-expression profiling techniques to mycosis fungoides, an approach that should significantly expand our knowledge of the disease. First, they identify a 27-gene expression signature, using cDNA microarray analysis on 29 cases of mycosis fungoides and 11 cases of inflammatory dermatoses, which distinguishes between the two. From this they extract a set of 6 genes whose expression can discriminate between mycosis fungoides and inflammatory conditions in 97% of cases. The set of 27 mycosis fungoides-expressed genes, which includes a number of genes involved in the regulation of signaling by tumor necrosis factor (TNF), may hold clues to the pathogenesis of the disease. Finally, through hierarchical clustering of the gene expression data, the authors define 2 main groups of mycosis fungoides cases, one of which includes those that are more aggressive, including cases with tumor-stage disease.
Gene-expression analysis by microarray techniques has been utilized to refine tumor classification for a number of malignant neoplasms, including large B-cell nonHodgkin lymphoma and breast carcinoma.
Tracey and colleagues have now applied this method to a T-cell lymphoma, providing us with a new set of markers that may aid in disease diagnosis, as well as providing a preliminary gene-expression-based tumor classification scheme for mycosis fungoides. Future gene-expression profiling studies, to compare mycosis fungoides with the related Sézary syndrome, other T-cell lymphomas, and benign mimics, such as pseudolymphomatoid drug eruption, will further advance this diagnostically challenging field. Cancer. 1975; 36:842-854) to define risk in multiple myeloma (MM). In recent years the ␤ 2 -microglobulin (␤ 2 M) and C-reactive protein (CRP) have added to the prognostic arsenal (Bataille et al, Blood. 1992; 80:733-737) . Despite their longevity, both staging systems are limited by an inability to segregate risk accurately in all cases, a particular problem in such a heterogeneous disease. Indeed, until recently prognostic prediction has been something of an irrelevance since all patients with symptomatic disease received essentially the same therapy. Lately, however, the landscape has changed and identification of accurate prognostic biomarkers has assumed increasing importance since therapeutic options may now vary widely according to disease biology.
In this issue, Terpos and colleagues (page 1064) take a step in this direction by examining the roles of the receptor activator of nuclear factor B ligand (RANKL) and RANK/osteoprotegerin (OPG), which play a dominant role in osteoclast activation and probably in the bone disease common to MM patients (Mundy, Nat Rev Cancer. 2002; 2:584-593 ). The authors demonstrate that in 121 MM patients serum levels of sRANKL were elevated and correlated with bone disease. The sRANKL/OPG ratio was also increased and correlated with markers of bone resorption, osteolytic lesions, and markers of disease activity. More impressively perhaps, sRANKL/OPG ratio, CRP, and ␤2M were the only independent prognostic factors in multivariate analysis and, used together, defined a low-risk group having a 96% probability of survival at 5 years, as compared with 52% and 0% for the intermediate-and high-risk groups, respectively: a remarkable discriminatory power. The results suggest that the RANKL/OPG system is not only associated with MM bone disease but also impacts the biology of plasma cell growth as reflected by its influence on survival.
Predicting prognosis and defining therapy using novel biomarkers (as described herein), chromosome translocation status and gene expression profiles point the way to the future of MM care, but all require further study. Until confirmed in large prospective studies, user-friendly and sensitive prognostic tools such as the recently devised MM International Staging System (ISS), which employs ␤2M and albumin, deserve wide implementation, albeit with future refinement (Greipp et al, Hematol J. 2003 ;4:S42-S44). Multiple myeloma remains an incurable B-cell malignancy whose victims survive a median of about 4 years. Over the past decade new therapies and supportive measures have provided incremental gains. No effective monoclonal antibody therapy exists for myeloma, but that is not for want of trying. Promising immunotherapeutic strategies involving CD38, CD20, and other antigens have been touted but did not succeed (Ellis et al, J Immunol. 1995; 155:925-37; Maloney et al, Semin Hematol. 1999; 36: 30-33; Treon et al, Semin Oncol. 1999; 26: 97-106; Ozaki et al, Blood. 1999; 93:3922-3930; Gemmel et al, Ann Hematol. 2002; 81: 119-123) . These therapies failed because the antigens were not pan-specific myeloma cell antigens and, less commonly, because the monoclonals cross-reacted with similar epitopes present on other cell types (eg, spinal neurons), causing unanticipated toxicities. New candidates continue to be put forward (Satoh et al, J Clin Lab Anal. 2002; 16:79-85) . In this issue, Kumar and colleagues (page 1075) present flow-cytometric data regarding the CD52 antigen on clonal cells from patients with plasma cell disorders and suggest that clinical trials be developed to test the efficacy of alemtuzumab (Campath-1H), a humanized monoclonal antibody (MoAb) against CD52, in myeloma and primary systemic amyloidosis.
Alemtuzumab antibodies recognize an epitope that consists of the C-terminal peptide and part of the glycosylphosphatidylinositol lipid anchor that binds CD52 to the cell membrane (Hale et al, Blood. 1983; 62: 873-882) . CD52 is widely and densely expressed on human lymphocytes (T and B cells, monocytes, and some dendritic cells; Ratzinger et al, Blood. 2003; 101:1422 -1429 and in the male reproductive tract. Alemtuzumab is a human IgG1 that binds to all human IgG Fc receptors and activates both complement and antibody-dependent cellular cytotoxicity (ADCC). Over the past decade anti-CD52 immunotherapy has been used to prevent acute graft-versus-host disease and graft rejection in reduced intensity allogeneic bone marrow transplantation, and to treat chronic lymphocytic leukemia (CLL) and autoimmune diseases. In May 2001 alemtuzumab was approved by the FDA for the treatment of patients with CLL who have failed alkylating agents and fludarabine. Its use has been associated with significant immunosuppression and in the allograft setting with a risk of late infections (Kottaridis et al, Blood. 2000; 96; 2419 -2425 .
Why not myeloma? Is alemtuzumab the one? Maybe. But given the track record of prior immunotherapies, a modicum of skepticism is in order. One problem is that the fraction of plasma cells expressing CD52 is low and likely quite variable. Kumar and colleagues report that, of 23 myeloma patients tested, half had CD52 on their malignant plasma cells. They also report that a median of 23% of the malignant plasma cells expressed the antigen and that 7 myeloma cell lines either minimally displayed or did not express CD52. To what degree the CD52 antigen on plasma cells would allow complement activation is also unclear. The clinical trials obviously should be restricted to patients whose malignant plasma cells express a certain density of CD52. The ideal population might be CD52 ϩ myeloma patients with persistent minimally responsive disease within 6 months of autologous hematopoietic cell transplantation, a time when ADCC may be enhanced. Risks of infectious complications and broad-spectrum prophylaxis would be important features of such a trial.
-Raymond L. Comenzo
Memorial Sloan-Kettering Cancer Center
A new von Hippel-Lindau disease
Molecular genetic analysis of inherited human disease has an exemplary record of informing our understanding of complex biologic processes. In keeping with this, recent studies of inherited erythrocytosis have provided important insights into physiologic mechanisms that govern oxygen homeostasis. Analysis of an apparently geographically restricted form of recessively inherited erythrocytosis, which is endemic
